Definium Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 4 days.
- Its last 6 Sell calls were actually followed by a +31% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is +61.5% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has fallen to 7.2% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -64.1% | Better than 8% |
| Return on invested capital | -59.5% | Better than 5% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -36.9% | Better than 13% |
| 6-month return | 26.0% | Better than 87% |
| 12-month return (ex latest month) | 234.0% | Better than 99% |
| Distance below 52-week high | 43.0% | Better than 25% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 6.3x | Better than 90% |
| Debt to assets | 9.2% | Better than 71% |
| Interest coverage | -32.5x | Better than 8% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 162.2% | Better than 91% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 29.48
- Open
- 29.14
- Day range
- 28.18 - 29.51
- Avg price
- 28.86
- Volume
- 3.24M
- Turnover
- 93.44M
- Turnover ratei
- 2.53%
- Volume ratioi
- 1.83
- Amplitudei
- 4.51%
- 52-week rangei
- 10.53 - 49.70
Valuation
- P/Ei
- -13.76
- P/E (TTM)i
- -9.71
- P/Bi
- 4.01
- EPSi
- -2.06
- Book value / shi
- 7.07
- Net profit
- -282.01M
- Net assets
- 968.02M
Share structure
- Market cap
- 3.88B
- Float capi
- 3.63B
- Shares out
- 136.90M
- Float sharesi
- 128.19M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
43.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+36.58M net over the window
Short interest
- Shares short
- 9.61M
- % of floati
- 7.16%
- Days to coveri
- 5.77
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Definium Therapeutics (DFTX)?
Definium Therapeutics last traded at 28.34. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Definium Therapeutics's market cap?
About 3.88B.
What is the P/E ratio of Definium Therapeutics?
The trailing twelve-month P/E is -9.71. The Valuation tab shows it against the stock's own five-year range.
Does Definium Therapeutics pay a dividend?
Definium Therapeutics does not currently pay a regular dividend.
Is Definium Therapeutics a buy according to analysts?
The consensus of 14 analysts is a Buy rating, with an average 12-month price target of 74.31, which implies 162.2% upside from the current price. This is not investment advice.
What is Definium Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Definium Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:02:39 · For reference only, not investment advice and not tailored to your situation.
Definium Therapeutics discussion 0 comments